Gilead Sciences (NASDAQ: GILD)once was a favorite for biotech investors. That hasn't been the case over the past couple of years, though. The big biotech fell out of favor with investors as sales for its hepatitis C virus (HCV) drugs plunged, dragging Gilead's overall revenue and earnings down in the process.
Is Gilead Sciences, Inc. (GILD) a Buy?
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться